https://doi.org/10.1080/ 2162402X.2019.1652539 . 5. Wada S, Jackson CM, Yoshimura K, Yen H-R, Getnet D, Harris TJ, et al. Sequencing CTLA-4 blockade with cell-based immu-notherapy for prostate cancer. J Transl Med. 2013;11:89. 6. Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD- 1(+)CD38(hi) cells and anti-PD-1 resistance. Nat Immunol. 2019;20:1231 –43. 7. Oh J, Barve M, Matthews CM, Koon EC, Heffernan TP, Fine B, et al. Phase II study of Vigil(R) DNA engineered immunotherapyas maintenance in advanced stage ovarian cancer. Gynecol Oncol.2016;143:504 –10. 8. Barve M, Kuhn J, Lamont J, Beitsch P, Manning L, Pappen B. et al. Follow-up of bi-shRNA furin/GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil ®in patients with advanced mela noma. Biomed Genet Genomics. 2016;1:8186. 9. Senzer N, Barve M, Nemunaitis J, Kuhn J, Melnyk A, Beitsch P, et al. Long term follow up: Phase I Trial of “bi-shRNA furin/ GMCSF DNA/Autologous Tumor Cell ”Immunotherapy (FANG™) in advanced cancer. J Vaccines Vaccin.